Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company''s lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
最新股票文章

為何麥可·貝瑞(Michael Burry)剛剛清倉所有股票
麥可·貝瑞剛剛拋售了超過7,000萬美元的股票,清空了他的整個投資組合,只保留一支股票,並對這家公司加碼,而其他投資人則紛紛出逃。
18:37, 22 7月 2025

道瓊交易觀察:財報季成為市場焦點
上週,美國主要股指表現分化,其中道瓊工業指數表現相對落後於科技權重較高的指數,但從技術面來看,道瓊仍維持多頭趨勢,並持續受到CoT(持倉報告)投機者的淨多頭偏好所支撐。
17:26, 21 7月 2025